However, analysis of individual patient samples showed that the AKT inhibitor reduced the percentage of divided CLL cells in a concentration-dependent manner in six out of the eight cases (Figure 5A, blue symbols). The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.